A blood-based colorectal cancer test was found to be the most cost-effective alternative colorectal cancer test for people who didn’t want a colonoscopy or fecal immunochemical test, according to a study published in the Journal of the National Cancer Institute.
Researchers used the microsimulation screening analysis-colon model to evaluate the cost-effectiveness of screening with capsule endoscopy, computed tomographic colonography, multitarget stool DNA tests and the mSEPT9 blood test, according to the February 2021 study. They also compared the alternatives with FIT and colonoscopy screenings.